Australian Clinical Labs (ACL) H2 2025 earnings summary

Executive summary

• Achieved strong earnings and cash flow growth in FY25, with revenue up 6.4% to $741.3 million and underlying EBIT up 8.7% to $68 million, despite challenging market conditions.

• Delivered against revenue and EBIT guidance, with margin expansion and robust free cash flow supporting significant capital returns to shareholders.

• Maintained a sustainable competitive advantage as the only national pathology provider with a single national laboratory information system, driving cost efficiencies and customer service enhancements.

Financial highlights

• Revenue reached $741.3 million, up 6.4% year-over-year; underlying EBIT was $68 million, up 8.7%, and EBIT margin improved to 9.2%.

• Underlying EPS increased 13.4% to $0.178 per share; underlying NPAT was $34 million, up 7.7%.

• Free cash flow before interest, tax, and financing rose over 30% to $70.8 million, with free cash flow conversion at 113.6% of cash EBITDA.

• Returned $44 million to shareholders via dividends and share buyback, including a final fully franked dividend of $0.09 per share and total FY dividend of $0.125 per share.

• Net debt/EBITDA reduced to 0.3x, with $13 million of debt repaid and working capital improved via better debtor collection.

Outlook and guidance

• FY26 revenue guidance: $760 million–$780 million; underlying EBIT: $67 million–$73 million.

• Guidance reflects ongoing market softness, patient rebate cuts, and restructuring to remove underperforming sites and contracts.

• Initiatives in development expected to generate at least $8 million EBIT in FY27, mainly from digital billing and operational efficiencies.

• Guidance does not include potential impacts from the Fair Work Commission's review of gender-based undervaluation in modern awards.